TY - JOUR
T1 - Machine Learning Prediction of Response to Cardiac Resynchronization Therapy
T2 - Improvement Versus Current Guidelines
AU - Feeny, Albert K.
AU - Rickard, John
AU - Patel, Divyang
AU - Toro, Saleem
AU - Trulock, Kevin M.
AU - Park, Carolyn J.
AU - Labarbera, Michael A.
AU - Varma, Niraj
AU - Niebauer, Mark J.
AU - Sinha, Sunil
AU - Gorodeski, Eiran Z.
AU - Grimm, Richard A.
AU - Ji, Xinge
AU - Barnard, John
AU - Madabhushi, Anant
AU - Spragg, David D.
AU - Chung, Mina K.
N1 - Funding Information:
Dr Rickard has been a speaker for Boston Scientific and consultant for Medtron-ic. Dr Niebauer has received research support from Biosense Webster, Biotronik, Boston Scientific, Medtronic, St. Jude Medical, and Sorin. Dr Varma has received consulting fees and honoraria from St. Jude Medical, Boston Scientific, Sorin, Biotronik, and Medtronic. Dr Gorodeski has received research support and consulting fees from Abott. Dr Madabhushi is an equity holder in Elucid Bioimaging and in Inspirata. He is also a scientific advisory consultant for Inspi-rata. In addition, he has served as a scientific advisory board member for Inspi-rata, Astrazeneca, and Merck. He also has sponsored research agreements with Philips and Inspirata. His technology has been licensed to Elucid Bioimaging and Inspirata. He is also involved in a NIH U24 grant with PathCore, and 3 different R01 grants with Inspirata. Dr Chung serves on a steering committee and is a speaker for EPIC Alliance—a forum for networking and mentoring of women in cardiac electrophysiology sponsored by Biotronik but declines all honoraria from device companies. The other authors report no conflicts.
Funding Information:
This study was supported by National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute grant R01-HL111314; an American Heart Association Atrial Fibrillation Strategically Focused Research Network grant; NIH UL1-RR024989—NIH National Center for Research Resources for Case Western Reserve University and Cleveland Clinic Clinical and Translational Science Award; and by the Center of Excellence in Cardiovascular Translational Functional Genomics, Heart and Vascular Institute and Lerner Research Institute funds. This study was also supported by Tomsich Atrial Fibrillation Research Fund; Heart and Vascular Institute and Lerner Research Institute Philanthropy funds; National Cancer Institute/NIH: 1U24CA199374-01, R01CA202752-01A1, R01CA208236-01A1, R01-CA216579-01A1, R01-CA220581-01A1, 1U01-CA239055-01; National Center for Research Resources 1-C06 RR12463-01; received Veterans Affairs (VA) Merit Review Award IBX004121A from the VA Biomedical Laboratory Research and Development Service; Department of Defense (DOD) Prostate Cancer Idea Development Award (W81XWH-15-1-0558); DOD Lung Cancer Investigator-Initiated Translational Research Award (W81X-WH-18-1-0440). This study was also supported by DOD Peer-Reviewed Cancer Research Program (W81XWH-16-1-0329); Ohio Third Frontier Technology Validation Fund; and Wallace H. Coulter Foundation Program in the Department of Biomedical Engineering and the Clinical and Translational Science Award Program at Case Western Reserve University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, VA, DOD, or US Government.
Publisher Copyright:
© 2019 American Heart Association, Inc.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Background: Cardiac resynchronization therapy (CRT) has significant nonresponse rates. We assessed whether machine learning (ML) could predict CRT response beyond current guidelines. Methods: We analyzed CRT patients from Cleveland Clinic and Johns Hopkins. A training cohort was created from all Johns Hopkins patients and an equal number of randomly sampled Cleveland Clinic patients. All remaining patients comprised the testing cohort. Response was defined as ≥10% increase in left ventricular ejection fraction. ML models were developed to predict CRT response using different combinations of classification algorithms and clinical variable sets on the training cohort. The model with the highest area under the curve was evaluated on the testing cohort. Probability of response was used to predict survival free from a composite end point of death, heart transplant, or placement of left ventricular assist device. Predictions were compared with current guidelines. Results: Nine hundred twenty-five patients were included. On the training cohort (n=470: 235, Johns Hopkins; 235, Cleveland Clinic), the best ML model was a naive Bayes classifier including 9 variables (QRS morphology, QRS duration, New York Heart Association classification, left ventricular ejection fraction and end-diastolic diameter, sex, ischemic cardiomyopathy, atrial fibrillation, and epicardial left ventricular lead). On the testing cohort (n=455, Cleveland Clinic), ML demonstrated better response prediction than guidelines (area under the curve, 0.70 versus 0.65; P=0.012) and greater discrimination of event-free survival (concordance index, 0.61 versus 0.56; P<0.001). The fourth quartile of the ML model had the greatest risk of reaching the composite end point, whereas the first quartile had the least (hazard ratio, 0.34; P<0.001). Conclusions: ML with 9 variables incrementally improved prediction of echocardiographic CRT response and survival beyond guidelines. Performance was not improved by incorporating more variables. The model offers potential for improved shared decision-making in CRT (online calculator: http://riskcalc.org:3838/CRTResponseScore). Significant remaining limitations confirm the need to identify better variables to predict CRT response.
AB - Background: Cardiac resynchronization therapy (CRT) has significant nonresponse rates. We assessed whether machine learning (ML) could predict CRT response beyond current guidelines. Methods: We analyzed CRT patients from Cleveland Clinic and Johns Hopkins. A training cohort was created from all Johns Hopkins patients and an equal number of randomly sampled Cleveland Clinic patients. All remaining patients comprised the testing cohort. Response was defined as ≥10% increase in left ventricular ejection fraction. ML models were developed to predict CRT response using different combinations of classification algorithms and clinical variable sets on the training cohort. The model with the highest area under the curve was evaluated on the testing cohort. Probability of response was used to predict survival free from a composite end point of death, heart transplant, or placement of left ventricular assist device. Predictions were compared with current guidelines. Results: Nine hundred twenty-five patients were included. On the training cohort (n=470: 235, Johns Hopkins; 235, Cleveland Clinic), the best ML model was a naive Bayes classifier including 9 variables (QRS morphology, QRS duration, New York Heart Association classification, left ventricular ejection fraction and end-diastolic diameter, sex, ischemic cardiomyopathy, atrial fibrillation, and epicardial left ventricular lead). On the testing cohort (n=455, Cleveland Clinic), ML demonstrated better response prediction than guidelines (area under the curve, 0.70 versus 0.65; P=0.012) and greater discrimination of event-free survival (concordance index, 0.61 versus 0.56; P<0.001). The fourth quartile of the ML model had the greatest risk of reaching the composite end point, whereas the first quartile had the least (hazard ratio, 0.34; P<0.001). Conclusions: ML with 9 variables incrementally improved prediction of echocardiographic CRT response and survival beyond guidelines. Performance was not improved by incorporating more variables. The model offers potential for improved shared decision-making in CRT (online calculator: http://riskcalc.org:3838/CRTResponseScore). Significant remaining limitations confirm the need to identify better variables to predict CRT response.
KW - algorithms
KW - cardiac resynchronization therapy
KW - heart failure
KW - machine learning
KW - patient selection
UR - http://www.scopus.com/inward/record.url?scp=85068456706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068456706&partnerID=8YFLogxK
U2 - 10.1161/CIRCEP.119.007316
DO - 10.1161/CIRCEP.119.007316
M3 - Article
C2 - 31216884
AN - SCOPUS:85068456706
SN - 1941-3149
VL - 12
JO - Circulation: Arrhythmia and Electrophysiology
JF - Circulation: Arrhythmia and Electrophysiology
IS - 7
M1 - e007316
ER -